Table 3.

Clinical trials on immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Agent	Clinical trial number	Phase, design	Primary end point	Status⁎
Phase II and III trials with immune checkpoint inhibitors
Nivolumab vs. sorafenib	NCT02576509	Phase III, first-line	Overall survival	Active, not recruiting
Pembrolizumab vs. best supportive care	NCT02702401	Phase III, after sorafenib	Overall survival and progression-free survival	Active, not recruiting
Atezolizumab + bevacizumab vs. sorafenib	NCT03434379	Phase III, first-line	Overall survival and progression-free survival	Recruiting
Durvalumab ± tremelimumab vs. sorafenib	NCT03298451	Phase III, first-line	Overall survival	Recruiting
BGB-A317 vs. sorafenib	NCT03412773	Phase III, first-line	Overall survival	Recruiting
Avelumab	NCT03389126	Phase II, after sorafenib	Response rate	Recruiting
Targeted therapy + immune checkpoint inhibitor combinations
Nivolumab + cabozantinib	NCT01658878	Phase I/II, multicohort	Safety and response rate	Active, not recruiting
Nivolumab + lenvatinib	NCT03418922	Phase I	Safety	Recruiting
Nivolumab + sorafenib	NCT03439891	Phase I/II	Safety and response rate	Recruiting
Nivolumab + bevacizumab	NCT03382886	Phase I	Safety	Recruiting
Pembrolizumab + lenvatinib	NCT03006926	Phase I	Safety	Recruiting
Pembrolizumab + regorafenib	NCT03347292	Phase I	Safety	Recruiting
Avelumab + axitinib	NCT03289533	Phase I	Safety	Recruiting
PDR001 + sorafenib	NCT02988440	Phase I	Safety	Recruiting
Immuno-oncology agents in combination
Nivolumab + ipilimumab	NCT01658878	Phase I/II, multicohort	Safety and response rate	Active, not recruiting
Durvalumab ± tremelimumab	NCT02519348	Phase I/II	Safety and response rate	Recruiting
Nivolumab + galunisertib	NCT02423343	Phase I/II	Safety, response rate, progression-free and overall survival	Recruiting
Nivolumab + pexastimogene devacirepvec	NCT03071094	Phase I/II	Safety and response rate	Recruiting

^*Status on December 1^st, 2018 at clinicaltrial.gov.